Maxim downgraded scPharmaceuticals (SCPH) to Hold from Buy after the company agreed to be acquired by MannKind (MNKD) for $5.35 per share in cash at closing plus one non-tradable contingent value right per share to receive certain milestone payments of up to an aggregate of $1.00 per CVR in cash, for total consideration of up to $6.35 per share.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPH:
- scPharmaceuticals Announces Merger with MannKind Corporation
- MannKind to acquire scPharmaceuticals for up to $6.35 per share in cash
- scPharmaceuticals Extends SmartDose Supply Agreement
- scPharmaceuticals receives Notices of Allowance from USPTO for SCP-111
- scPharmaceuticals Q2 2025 Earnings Call Highlights Growth